Skip to content

Revvity RVTY BRAZIL — Total net long-lived assets

Discontinued — last reported Q4 '20

Similar metrics at other companies

Crown Holdings logo
CCKBrazil — Long-Lived Assets
$503M+5.2%
CNH Industrial N.V. logo
CNHBrazil — Total long-lived assets
$265M+31.2%
Corpay logo
CPAYBrazil — Long-lived assets (excluding goodwill)
$66.58M+25.1%
AES logo
AESBrazil — Long-Lived Assets
$0
Corpay logo
CPAYBrazil — Long-lived assets (excluding goodwill, intangibles, investments and other)
$53.24M+10.9%
BioMarin Pharmaceuticals logo
BMRNRest of world — Total long-lived assets
$20.84M+53.2%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:NoncurrentAssets.

The official record: Revvity’s 10-K, filed March 2, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does BRAZIL — total net long-lived assets mean?
The total value of the company's long-term physical and intangible assets located in Brazil after accounting for wear and tear.
How do you interpret BRAZIL — total net long-lived assets?
An increase suggests capital expansion or investment in local infrastructure, while a decrease may indicate asset divestment, impairment, or depreciation outpacing new capital expenditures.
How does BRAZIL — total net long-lived assets compare across companies?
Peers in the life sciences and diagnostics sectors typically report similar geographic asset concentrations to demonstrate regional market commitment and supply chain localization.